Previous 10 | Next 10 |
Ault Alliance Congratulates Alzamend Neuro on This Important and Historic Milestone in Clinical Drug Discovery and Development Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“ Ault Alliance ” or the “ Company ”), is prou...
2023-04-03 09:09:47 ET Alzamend Neuro ( NASDAQ: ALZN ) has started a phase 1/2a trial of ALZN002, an immunotherapy vaccine for mild to moderate Alzheimer's dementia. The trial, which will enroll 20-30 participants, will evaluate the safety, tolerability, and efficacy of AL...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD...
Topline data expected in June 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ...
2023-03-16 10:08:56 ET Alzamend Neuro press release ( NASDAQ: ALZN ): Q3 GAAP EPS of -$0.06. At January 31, 2023, cash was $7.4 million, and working capital was $5.8 million. Net cash used in operations was $6.7 million during the nine months ended January 31, 2023. ...
Company had $7.4 Million Cash at January 31, 2023 Additional Non-Dilutive Capital via Note Receivable of $14.8 Million Expected in December 2023 Initiation of Phase I/IIA Clinical Trial for ALZN002 to Treat Mild to Moderate Dementia of the Alzheimer’s Type Expected ...
Presentation on Thursday, February 2, 2023 at 10:30 a.m. ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer...
Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clini...
Alzamend Neuro ( NASDAQ: ALZN ) said on Wednesday that it expects topline data from a Phase IIA trial for AL001 treatment of dementia related to Alzheimer’s in second quarter of 2023. The company also said it was partnering with the Miller School of Medicine, Inte...
Topline Data for Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s Expected in Second Quarter of 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical compan...
News, Short Squeeze, Breakout and More Instantly...
Alzamend Neuro Inc. Company Name:
ALZN Stock Symbol:
NASDAQ Market:
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...